<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Induction of labor: Techniques for preinduction cervical ripening</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Induction of labor: Techniques for preinduction cervical ripening</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Induction of labor: Techniques for preinduction cervical ripening</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William Grobman, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Malavika Prabhu, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 29, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>When labor is induced, cervical status has an impact on the duration of induction and the likelihood of vaginal birth. If the cervical status is unfavorable, a ripening (also called priming) process is generally employed prior to induction to shorten the duration of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> administration and maximize the possibility of vaginal birth.</p><p>The two major techniques for cervical ripening are (1) mechanical interventions, such as insertion of a balloon catheter or, less commonly, hygroscopic cervical dilators, and (2) application of pharmacologic agents, such as prostaglandins. These techniques will be reviewed in this topic. General issues regarding induction of labor and use of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> are discussed separately (see  <a class="medical medical_review" href="/d/html/4476.html" rel="external">"Induction of labor with oxytocin"</a>). Cervical preparation before surgical pregnancy termination is also discussed separately. (See  <a class="medical medical_review" href="/d/html/111284.html" rel="external">"Pregnancy termination: Cervical preparation for procedural abortion"</a>.) </p><p class="headingAnchor" id="H3153628469"><span class="h1">GENERAL APPROACH</span></p><p class="headingAnchor" id="H4289516106"><span class="h2">Candidates</span><span class="headingEndMark"> — </span>Patients with unfavorable cervixes are candidates for cervical ripening. Compared with use of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> alone, cervical ripening probably increases the chances of achieving vaginal birth within 24 hours and does not increase, and may decrease, the risk for cesarean birth.</p><p>There is no universally accepted definition of favorable or unfavorable cervix. Many clinicians consider a Bishop score &lt;6  (<a class="graphic graphic_table graphicRef65320" href="/d/graphic/65320.html" rel="external">table 1</a>) indicative of an unfavorable cervix and the need for a ripening agent, while others use a lower threshold (eg, ≤3 or 4) [<a href="#rid1">1</a>].</p><p>If the cervix is assessed to be favorable, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> typically is initiated for induction without use of a cervical ripening agent. (See  <a class="medical medical_review" href="/d/html/4476.html" rel="external">"Induction of labor with oxytocin"</a>.)</p><p class="headingAnchor" id="H1741666696"><span class="h2">Inpatient versus outpatient cervical ripening</span><span class="headingEndMark"> — </span>Historically, most patients have undergone cervical ripening in the hospital. Outpatient approaches to cervical ripening (in circumstances when maternal and/or fetal monitoring are not otherwise necessary during the ripening phase) are feasible and could be useful for reducing the duration of hospitalization and costs of medical care [<a href="#rid2">2-6</a>]. Investigators have used mechanical methods or prostaglandins for outpatient ripening; in the United States, there has been a tendency to prefer mechanical methods (eg, intracervical balloon, hygroscopic dilators) because prostaglandins are associated with a greater chance of tachysystole and the related theoretic concern that they would not be as safe in the outpatient setting. Large trials with the power to detect differences in meaningful outcomes (either between inpatient versus outpatient ripening or between different outpatient ripening regimens) have not yet been performed, and as such, the available body of evidence does not support a recommendation for a specific approach [<a href="#rid7">7</a>]. Correspondingly, institutional approaches to outpatient cervical ripening vary widely.</p><p>A 2016 survey of United Kingdom obstetric providers indicated that more than 17 percent of units were currently or soon-to-be providing outpatient induction of labor [<a href="#rid8">8</a>]. The vast majority began the procedures in the hospital, used the time-released prostaglandin E2 (PGE2) insert, and monitored patients with cardiotocodynamometry after insertion.</p><p>Investigators in the United States have reported on their experience with outpatient preinduction cervical ripening using a balloon catheter in selected patients [<a href="#rid9">9-12</a>]. Synthetic hygroscopic cervical dilators (eg, Dilapan-S) have also been used and have the advantages of no protrusion from the introitus and no need to keep under tension, but can be more costly than balloon catheters. The procedure generally has been limited to low-risk individuals with a singleton, live, vertex fetus at ≥37 weeks of gestation; exclusion criteria have included previous cesarean birth, gestational hypertension or preeclampsia, fetal growth restriction, prelabor rupture of membranes, and factors that could preclude prompt return to the hospital in the event an urgent return is needed.</p><p>The cost-effectiveness of outpatient cervical ripening compared with an inpatient approach has not been established. In an Australian cost-effectiveness analysis run in parallel with a small randomized trial of inpatient prostaglandin gel administration versus outpatient catheter placement, the outpatient arm was not more cost-effective [<a href="#rid13">13</a>]. Although outpatient balloon catheter use resulted in fewer predelivery inpatient hours and costs, it did not reduce overall inpatient hours and failed to achieve comparable rates of vaginal birth within 12 hours of birthing unit admission. In a randomized trial in the United States comparing the inpatient versus outpatient setting in nulliparas who underwent cervical ripening with a balloon catheter, outcomes were similar, but the outpatient group had a shorter time (4.3 fewer hours) between hospital admission and birth [<a href="#rid12">12</a>]. </p><p class="headingAnchor" id="H2623104187"><span class="h2">Protocol</span><span class="headingEndMark"> — </span>Institutions should create and follow a clear protocol that delineates not only general cervical ripening issues, but also distinguishes differences between inpatient and outpatient ripening (eg, eligibility criteria).</p><p>The protocol should:</p><p class="bulletIndent1"><span class="glyph">●</span>Describe preripening patient evaluation and criteria (eg, reactive nonstress test or biophysical profile score ≥8, confirmation of presentation, confirmation that the cervix is unfavorable).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>List contraindications for outpatient cervical ripening. There are no absolute medical contraindications to inpatient cervical ripening in patients who are candidates for labor and vaginal birth and have no sensitivities to the drug/device that will be used. Contraindications exist for outpatient cervical ripening since continuous maternal and fetal monitoring and prompt intervention are not possible. Some examples of contraindications to outpatient ripening that have been employed are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Fetal conditions</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Fetal growth restriction</p><p class="bulletIndent3"><span class="glyph">-</span>Oligohydramnios or polyhydramnios </p><p class="bulletIndent3"><span class="glyph">-</span>Multiple gestation</p><p class="bulletIndent3"><span class="glyph">-</span>Major fetal anomalies</p><p class="bulletIndent3"><span class="glyph">-</span>Nonreassuring fetal assessment</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Maternal conditions</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prior cesarean birth or uterine surgery involving removal of a full thickness of uterine tissue</p><p class="bulletIndent3"><span class="glyph">-</span>Clinically significant vaginal bleeding</p><p class="bulletIndent3"><span class="glyph">-</span>Hypertensive disorders of pregnancy</p><p class="bulletIndent3"><span class="glyph">-</span>A patient who is unable to return easily should symptoms arise</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Describe the fundamental steps of the procedure.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Include a defined period of monitoring after initiation of ripening to assess for conditions (eg, nonreactive fetal heart rate [FHR], membrane rupture) that would preclude cessation of continuous monitoring if ripening is being performed as an inpatient procedure or preclude discharge of the patient to home if ripening is being performed with the expectation of outpatient use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Provide patient instructions for activity (eg, shower but no bathing), when to call the provider (eg, excessive bleeding, fever, labor, membrane rupture), and when to return to the hospital.</p><p></p><p class="headingAnchor" id="H4121077179"><span class="h2">Choice of ripening agent for inpatient procedures</span><span class="headingEndMark"> — </span>The following text and general principles apply to inpatient ripening. There is much less data derived from trials of outpatient cervical ripening.</p><p class="bulletIndent1"><span class="glyph">●</span>The choice of ripening agent should be based on provider and patient preference. There is no single, clear best practice with respect to the choice of agent used for cervical ripening: both mechanical and pharmacologic agents are acceptable options, unless the patient has a contraindication to use of a specific agent or technique. (See <a class="local">'Contraindications'</a> below and <a class="local">'Contraindications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A single method may be used (ie, either mechanical or pharmacologic), a mechanical method may be combined with a pharmacologic method (see <a class="local">'Combination therapy (balloon catheter plus a prostaglandin or oxytocin)'</a> below), or mechanical and pharmacologic methods may be used sequentially until cervical ripening is achieved.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Balloon catheters have no or minimal side effects but necessitate a potentially uncomfortable vaginal procedure for catheter insertion. They have convenient storage requirements (eg, no refrigeration), which is an issue for some prostaglandin agents. (See <a class="local">'Side effects'</a> below.)</p><p></p><p class="bulletIndent1">Prostaglandins reduce the need for additional use of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> since prostaglandins promote myometrial contractility [<a href="#rid14">14,15</a>]. Disadvantages include the potential for excessive uterine activity leading to FHR abnormalities, and side effects (eg, diarrhea). However, in clinical trials, neither the advantages nor disadvantages resulted in differences in clinically important outcomes (eg, cesarean birth or neonatal morbidity rates). (See <a class="local">'Side effects'</a> below.)</p><p></p><p class="headingAnchor" id="H1830709147"><span class="h3">Evidence</span><span class="headingEndMark"> — </span>A 2016 network meta-analysis comparing the use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> (oral, vaginal), <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a>, and the balloon catheter for cervical ripening concluded that no method was clearly superior in terms of the rate of failure to achieve vaginal birth within 24 hours, tachysystole with adverse FHR changes, and cesarean birth [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Use of vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> or vaginal <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> reduced the risk of failure to achieve vaginal birth within 24 hours compared with use of a balloon catheter, oral misoprostol, or intracervical dinoprostone, but increased the risk of uterine hyperstimulation with adverse FHR changes compared with other agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of a balloon catheter for cervical ripening resulted in the lowest risk of uterine hyperstimulation with adverse FHR changes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> resulted in the lowest risk of cesarean birth.</p><p></p><p>The analysis did not consider combined methods (balloon catheter and concurrent prostaglandin or <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>), which in some studies have shortened the time to vaginal birth and are becoming increasingly common. </p><p>Interpretation of data on cervical ripening is hindered by several factors, which make it difficult to identify the methods of cervical ripening and labor induction, either used alone or in combination, that are most effective and safe. These factors include: </p><p class="bulletIndent1"><span class="glyph">●</span>A basic lack of understanding of the physiologic events that initiate and sustain labor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Wide biologic variation in the progress of normal labor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Failure of studies to distinguish between cervical ripening and labor induction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Iatrogenic variation in indications for induction and management of induced labor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Variation in parity and gestational age at induction, as well as other demographic features that affect clinical results.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of different clinical endpoints in research studies (eg, change in cervical status versus length of labor versus route of birth).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Few trials comparing multiple methods.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate data on patient-reported outcomes, such as satisfaction.</p><p></p><p class="headingAnchor" id="H3745743635"><span class="h2">Initiation and discontinuation</span><span class="headingEndMark"> — </span>Once a cervical ripening agent is initiated, the process is typically continued until the cervix is favorable  (<a class="graphic graphic_algorithm graphicRef135242" href="/d/graphic/135242.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef65320" href="/d/graphic/65320.html" rel="external">table 1</a>). There is no evidence-based time cutoff that prohibits continued efforts at cervical ripening with the same or different methods when the cervix remains unfavorable. However, when using a balloon catheter, many clinicians will not continue efforts at cervical ripening if it falls out or if membranes spontaneously rupture. </p><p class="headingAnchor" id="H440262575"><span class="h1">MECHANICAL METHODS</span></p><p class="headingAnchor" id="H178705754"><span class="h2">Overview of use</span></p><p class="headingAnchor" id="H3661569781"><span class="h3">Types</span><span class="headingEndMark"> — </span>Insertion of a balloon catheter (eg, Foley bladder catheter) through the endocervical canal and into the extraamniotic space is the most common mechanical method currently in use. Placement of hygroscopic dilators into the endocervical canal and extending through the internal cervical os is an alternative mechanical method.</p><p class="headingAnchor" id="H542256275"><span class="h3">Mechanism of action</span><span class="headingEndMark"> — </span>Mechanical methods of cervical ripening have been theorized to work both by direct physical pressure on the internal cervical os and by causing the release of prostaglandins from the decidua, adjacent membranes, and/or cervix [<a href="#rid17">17</a>]. These effects combine to promote a number of biochemical and biophysical changes that lead to cervical ripening and an increase in myometrial contractility.</p><p class="headingAnchor" id="H3542384811"><span class="h3">Contraindications</span><span class="headingEndMark"> — </span>For in-patient mechanical cervical ripening, there are few contraindications because the patient and fetus can be monitored frequently and rapid intervention for a warning sign is possible. For out-patient mechanical cervical ripening, there are additional contraindications to consider and practices vary among institutions. (See <a class="local">'Protocol'</a> above.)</p><p>Issues to consider:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>GBS</strong> – Group B <em>Streptococcus</em> (GBS) colonization is <strong>not</strong> a contraindication to use of mechanical methods of cervical ripening [<a href="#rid18">18</a>], but standard GBS antibiotic prophylaxis should be used when labor begins or at rupture of membranes, whichever occurs first. Antibiotic prophylaxis is reviewed separately. (See  <a class="medical medical_review" href="/d/html/438.html" rel="external">"Prevention of early-onset group B streptococcal disease in neonates", section on 'Patients undergoing obstetric procedures'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Polyhydramnios</strong> – Polyhydramnios is not an absolute contraindication to use if induction is indicated, as long as there are no other contraindications to labor induction and vaginal birth (eg, malpresentation, which is more likely in the setting of polyhydramnios).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low-lying placenta</strong> – A low-lying placenta is a relative contraindication since the edge of the placenta may be disrupted by manipulation during placement of the device. Placement should be individualized, including based on the patient's history of vaginal bleeding and the actual proximity of the placenta to the internal os.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ruptured membranes</strong> – Most practitioners, including the author of this topic, never place a balloon catheter for cervical ripening in patients with ruptured membranes, given concerns about increasing the risk of clinical chorioamnionitis and lack of benefit in this setting. If membranes are intact when the device is placed but then rupture at any time after placement, a common practice is to remove the device, but some practitioners limit the duration of cervical ripening to 12 hours in such patients. The approach is the same regardless of fetal status (alive or dead). The same considerations apply to preinduction cervical ripening with hygroscopic dilators, which are less commonly used for this indication (although commonly used for cervical preparation prior to surgical procedures for pregnancy termination).</p><p></p><p class="bulletIndent1">While there is not total consensus on optimal management in this setting, the package insert for the Cook Cervical Ripening Balloon lists ruptured membranes as a contraindication to placement and an indication for deflation and removal. The package insert for Dilapan-S lists clinically apparent genital tract infection as the only contraindication. Data on the safety and efficacy of balloon catheter use in patients with ruptured membranes are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6757.html" rel="external">"Prelabor rupture of membranes at term: Management", section on 'Active management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intact membranes with intraamniotic infection</strong> – In patients with intact membranes who are undergoing cervical ripening for labor induction, the use of a balloon catheter is not absolutely contraindicated in the uncommon scenario of intraamniotic infection.</p><p></p><p class="headingAnchor" id="H1283379940"><span class="h3">Side effects</span><span class="headingEndMark"> — </span>Mechanical methods of cervical ripening do not cause systemic side effects and are associated with a lower rate of tachysystole with fetal heart rate changes than prostaglandins [<a href="#rid19">19</a>]. Meta-analyses of randomized trials have not found convincing evidence of an increased risk of infectious morbidity in mothers or neonates exposed to mechanical methods of cervical ripening compared with those exposed to prostaglandins [<a href="#rid19">19,20</a>].</p><p>Importantly, these trials typically have excluded patients with ruptured membranes. Very limited data in patients with ruptured membranes, most of whom were at term, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/6757.html" rel="external">"Prelabor rupture of membranes at term: Management", section on 'Balloon catheter'</a>.)</p><p class="headingAnchor" id="H2713916749"><span class="h2">Balloon catheter</span></p><p class="headingAnchor" id="H1596979231"><span class="h3">Device selection</span><span class="headingEndMark"> — </span>A double-balloon catheter specifically designed for cervical ripening is commercially available  (<a class="graphic graphic_figure graphicRef61707" href="/d/graphic/61707.html" rel="external">figure 1</a>); alternatively, a single-balloon catheter (eg, Foley bladder catheter) can be used. In meta-analysis of randomized trials, there were no clinically important differences in outcomes with use of a double- versus a single-balloon catheter [<a href="#rid19">19</a>]. However, the single-balloon catheter is less expensive and is usually more readily available.</p><p class="headingAnchor" id="H2069454004"><span class="h3">Procedure</span><span class="headingEndMark"> — </span>The balloon catheter is placed using aseptic technique. Although uterine activity and fetal heart rate (FHR) are often continuously monitored while it is in place, numerous investigators have demonstrated the safety of only transient monitoring (30 to 120 minutes) after placement [<a href="#rid6">6,10,11</a>].</p><p>After the balloon catheter is extruded or removed, <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> is begun and amniotomy is performed, if technically possible [<a href="#rid21">21,22</a>]. Alternatively, oxytocin can be initiated concurrently with the catheter in place. (See <a class="local">'Combination therapy (balloon catheter plus a prostaglandin or oxytocin)'</a> below.)</p><p>In a randomized trial, amniotomy within one hour of balloon catheter expulsion shortened the time to birth and increased the frequency of birth within 24 hours compared with expectant management in which the median time to amniotomy was 10 hours after balloon catheter expulsion [<a href="#rid23">23</a>].</p><p class="headingAnchor" id="H2008546285"><span class="h4">Single-balloon catheter</span><span class="headingEndMark"> — </span>A balloon portion of a single-balloon catheter is placed in the extraamniotic space. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insert the catheter</strong> – Ring forceps can be used to pass a deflated single-balloon catheter through the internal cervical os and into the extraamniotic space [<a href="#rid24">24,25</a>]. Alternatively, the catheter can be inserted manually, similar to an intrauterine pressure catheter. This is usually possible even if the cervix is not dilated since the pregnant cervix is soft and distensible and rarely tightly closed. If it is difficult to pass the catheter, a urologic sound or other rigid device can be inserted into the catheter to facilitate placement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distend the balloon</strong> – The balloon is distended with 30 to 80 mL <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>. If a sound or other rigid device was used, it is removed before or while beginning instillation of saline. The dilated balloon is then gently retracted so that it rests against the internal os without extending into the endocervical canal.</p><p></p><p class="bulletIndent1">In a meta-analysis of randomized trials comparing use of larger (60 to 80 mL) versus smaller (30 mL) volumes during cervical ripening, larger balloon volumes resulted in a shorter time from induction to delivery (mean difference 1.97 hours, 95% CI -3.88 to -0.06) but had a similar cesarean birth rate, time to vaginal birth, time to catheter expulsion, and maternal and fetal complication rates [<a href="#rid26">26</a>]. These data suggest that either a large- or small-balloon volume is a reasonable choice.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintain tension</strong> – Many clinicians tape the end of the catheter to the inner thigh, placing it on tension, with readjustment to maintain tension at occasional intervals. A randomized trial noted a decrease in time to balloon expulsion when traction was used but no effect on the time to birth [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1">Some clinicians attach a weight (eg, 1 L of fluid) to the end of the catheter and suspend it from the end of the bed. Weighted traction may shorten the time to spontaneous expulsion but did not shorten the time to birth in two randomized trials [<a href="#rid27">27,28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Remove at 12 hours</strong> – The catheter is typically left in place until it is extruded; if not extruded, it is generally removed by 12 hours after insertion; however, there is no absolute contraindication to leaving the catheter in place for more than 12 hours.</p><p></p><p class="bulletIndent1">The 12-hour duration of use is supported by a randomized trial that found removing nonextruded catheters after 12 hours and beginning <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> resulted in significantly more vaginal births within 24 hours than waiting 24 hours before removal and oxytocin induction (60 versus 21 percent), and did not lead to an increase in cesarean birth [<a href="#rid29">29</a>]. </p><p></p><p class="bulletIndent1">There is evidence that a time shorter than 12 hours is reasonable. Four trials have reported a shorter time from insertion to delivery with planned removal at 6 rather than 12 hours, without increasing the cesarean birth rate [<a href="#rid30">30-33</a>]. One of the trials used combination therapy of catheter insertion plus <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> administration [<a href="#rid30">30</a>]. </p><p></p><p class="headingAnchor" id="H3788220072"><span class="h4">Double-balloon catheter</span><span class="headingEndMark"> — </span>The distal balloon of a double-balloon catheter is in the extraamniotic space adjacent to the internal os and the proximal balloon is in the vagina adjacent to the external os.</p><p>The procedure for inserting a double-balloon catheter is similar to that described above for the single-balloon catheter (see <a class="local">'Single-balloon catheter'</a> above), with the following modifications:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insertion</strong> – The catheter is inserted until the proximal balloon is in the cervical canal, at which point the distal balloon should be intrauterine and in the extraamniotic space.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Distension</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The distal intrauterine balloon is inflated with 40 mL <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> and gently retracted so that it rests against the internal os.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The proximal balloon, which should now be in the vagina outside the external os, is inflated with 20 mL <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a>.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the balloons are correctly situated on either end of the cervix, they can now be inflated with up to 80 mL <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> per balloon.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tension is not required</strong></p><p></p><p class="headingAnchor" id="H1265339209"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Use of balloon catheters has been associated with a 3.3 to 5.3 point mean change in Bishop score [<a href="#rid34">34</a>].</p><p>In meta-analyses of randomized trials:</p><p class="bulletIndent1"><span class="glyph">●</span>After balloon catheter placement, 94 percent of patients had a favorable cervix at 12 hours compared with 14 percent of those in the no treatment group (relative risk [RR] 0.07, 95% CI 0.03-0.19) [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon catheter and prostaglandin E2 (PGE2) were similarly effective for [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaginal birth not achieved in 24 hours (53.3 versus 52.8 percent; RR 1.01, 95% CI 0.82-1.26)</p><p class="bulletIndent2"><span class="glyph">•</span>Cesarean birth (23.8 percent in both groups; RR 1.00, 95% CI 0.92-1.09)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon catheter and low-dose vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Were similarly effective for vaginal birth not achieved in 24 hours (4.5 versus 4.1 percent; RR 1.09, 95% CI 0.85-1.39)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>But the balloon catheter had a higher frequency of cesarean birth (31.1 versus 24.3 percent; RR 1.28, 95% CI 1.02-1.60)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon catheter was less effective than low-dose oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> for [<a href="#rid19">19</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Vaginal birth not achieved in 24 hours (6.1 versus 4.8 percent; RR 1.28, 95% CI 1.13-1.46)</p><p class="bulletIndent2"><span class="glyph">•</span>Cesarean birth (25.9 versus 22.2 percent; RR 1.17, 95% CI 1.04-1.32)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon catheter resulted in lower risks of uterine tachysystole with FHR changes compared with prostaglandins (eg, 1.1 versus 3.1 percent with PGE2, RR 0.35, 95% CI 0.18-0.67; 1.3 versus 3.3 percent with vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, RR 0.39, 95% CI 0.18-0.85 [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The balloon catheter resulted in less serious neonatal morbidity or perinatal death compared with PGE2 (0.9 versus 2 percent; RR 0.48, 95% CI 0.25-0.93) [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The effect of the balloon catheter versus prostaglandins on serious maternal morbidity or death was uncertain (1 versus 3 per 1000 for PGE2, RR 0.20, 95% CI 0.01-4.1; 1 versus 2 per 1000 for low dose oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, RR 0.50, 95% CI 0.05-5.5) [<a href="#rid19">19</a>].</p><p></p><p>It should be noted, however, that much of the evidence in these meta-analyses was classified as low quality and when there was a statistical difference, the confidence intervals often approached unity.</p><p class="headingAnchor" id="H2787998894"><span class="h2">Hygroscopic dilators</span><span class="headingEndMark"> — </span>There are two types of hygroscopic dilators: One is made from natural seaweed (laminaria tents), and the other is a synthetic product (eg, Dilapan-S). Hygroscopic dilators are designed to absorb moisture and thus gradually expand within the cervical canal. In addition, disruption of the interface between the fetal membranes and decidua can lead to prostaglandin release, with consequent changes in cervical tissue beyond the passive mechanical stretching provided by the tent itself.</p><p>Hygroscopic dilators are as safe and effective as other cervical ripening agents [<a href="#rid36">36,37</a>], although they are more commonly used during pregnancy termination than for preinduction cervical ripening of term pregnancies. (See  <a class="medical medical_review" href="/d/html/3313.html" rel="external">"Overview of pregnancy termination", section on 'Cervical dilation and preparation'</a>.)</p><p>Although the balloon catheter has largely replaced use of hygroscopic dilators for induction of labor, some clinicians prefer to use hygroscopic dilators in patients with a prior cesarean birth. However, there is no strong evidence on which to base a recommendation favoring one approach over the other.</p><p class="headingAnchor" id="H3166119500"><span class="h3">Procedure</span></p><p class="bulletIndent1"><span class="glyph">●</span>After prepping the cervix and vagina with an antiseptic, the cervix is held with a nontraumatic clamp, if necessary, and the maximum number of dilators that the endocervical canal can accommodate are inserted without using excessive force; some cramping is common. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dipping the laminaria in a sterile lubricant before insertion may facilitate placement. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The dilators can be packed in place with two 4-by-4-inch gauze sponges tucked into the fornices; the number of dilators and gauze sponges that were inserted should be recorded in the patient's chart at insertion and at removal.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Laminaria typically are removed 12 to 24 hours after placement, whereas synthetic dilators can be removed sooner, after 6 to 8 hours.</p><p></p><p class="headingAnchor" id="H2134820378"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>In a meta-analysis of randomized trials, the risk of tachysystole with adverse FHR changes was lower in the laminaria group compared with the any prostaglandin group (0 versus 5.9 percent; RR 0.13, 95% CI 0.04-0.48, five trials, 538 participants). The risk of cesarean birth was similar for the laminaria, any prostaglandin and balloon catheter groups. The addition of either prostaglandins or <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> to laminaria during cervical ripening did not clearly improve the chances of vaginal birth within 24 hours or reduce the chances of cesarean birth.</p><p class="headingAnchor" id="H92003895"><span class="h1">PROSTAGLANDINS</span></p><p class="headingAnchor" id="H96999051"><span class="h2">General principles</span></p><p class="headingAnchor" id="H4206193784"><span class="h3">Mechanism of action</span><span class="headingEndMark"> — </span>Prostaglandins promote several biochemical and biophysical changes that lead to cervical ripening and an increase in myometrial contractility. The mechanisms involved in prostaglandin-induced cervical ripening are beyond the scope of this topic but have been reviewed in detail elsewhere [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H2276848"><span class="h3">Contraindications</span></p><p class="bulletIndent1"><span class="glyph">●</span>Allergy to prostaglandins and contraindications to labor and vaginal birth are absolute contraindications to cervical ripening with prostaglandins.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A prior cesarean birth or other prior major uterine surgery (eg, intramyometrial myomectomy that was likely to have significantly compromised the myometrium, repair of major congenital uterine anomalies) is a contraindication to use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> (prostaglandin E1) for cervical ripening because of the association with an increased risk for uterine rupture. However, in some countries use of prostaglandin E2 (PGE2) is acceptable in patients with prior uterine surgery who have no contraindication to a trial of labor. These data are reviewed separately. (See  <a class="medical medical_review" href="/d/html/4451.html" rel="external">"Cervical ripening and induction of labor after a prior cesarean birth", section on 'Use of prostaglandins'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preexisting regular painful uterine activity is a relative contraindication to use of prostaglandins, given that the addition of an exogenous uterotonic agent could prompt excessive uterine activity. When administering prostaglandins for cervical ripening, clinicians should be mindful of baseline uterine activity and consider delaying or avoiding administration if the patient is having two to three or more painful contractions/10 minutes. This is most important in patients who have already received at least one dose of prostaglandin as there appears to be a cumulative uterotonic effect. However, good evidence as to the best threshold of uterine activity for avoiding prostaglandins is not available. Clinicians should use their clinical judgment in making this decision, taking into account patient-specific factors such as grand multiparity, fetal status, the degree of discomfort/pain that the patient has experienced with previous doses, and the total number of doses of prostaglandins administered.</p><p></p><p class="headingAnchor" id="H2027444320"><span class="h3">Procedure</span></p><p class="bulletIndent1"><span class="glyph">●</span>Check uterine contraction frequency and intensity before administration. As discussed above, delaying or avoiding administration if the patient is having two to three or more painful contractions/10 minutes may reduce the risk of tachysystole. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Monitor uterine activity and fetal heart rate (FHR) continuously for at least 30 minutes after administration and maintain monitoring as long as regular uterine activity is present [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If labor does not ensue and the cervix remains unfavorable, options include repeated dosing (timing depends on the specific agent), adding or switching to a mechanical method, or initiating <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> (timing depends on the specific agent). (See <a class="local">'Use of specific agents'</a> below and  <a class="medical medical_review" href="/d/html/4476.html" rel="external">"Induction of labor with oxytocin", section on 'Oxytocin administration'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Perform amniotomy when feasible and safe to shorten the time interval to birth [<a href="#rid40">40,41</a>].</p><p></p><p class="headingAnchor" id="H2277345"><span class="h3">Side effects</span><span class="headingEndMark"> — </span>Side effects of prostaglandins include tachysystole, fever, chills, vomiting, and diarrhea. The frequency of these side effects depends upon the type of prostaglandin, dose, and route of administration. Uterine contractile abnormalities occur in up to 30 percent of patients, depending upon the vehicle and route of administration; other systemic effects occur in up to 5 percent of cases.</p><p><strong>Management</strong></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fever, chills, vomiting</strong> – Treatment of maternal discomfort is supportive (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, warm blanket, antiemetic drugs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tachysystole</strong> – If tachysystole with an abnormal FHR occurs after placement of a prostaglandin vaginal insert, removal of the insert usually reduces uterine contractility, normalizes the FHR, and does not appear to prolong the time to birth [<a href="#rid42">42</a>]. </p><p></p><p class="bulletIndent1">If a prostaglandin gel was applied, then removal of the remaining gel is not possible. A tocolytic drug (eg, <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> 250 mcg subcutaneously) can be administered if in utero resuscitation is indicated. Cervicovaginal lavage is not helpful for removing the drug or reversing adverse effects.</p><p></p><p class="bulletIndent1">If a <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> tablet was inserted, theoretically any remnants can be removed from the vagina. A tocolytic drug (eg, <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> 250 mcg subcutaneously) can be administered if in utero resuscitation is indicated.</p><p></p><p class="headingAnchor" id="H3780812968"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Multiple meta-analyses of randomized trials have established the efficacy of prostaglandins for cervical ripening (documented change in Bishop score) and improving the chances of vaginal birth within 12 or 24 hours, but a clear reduction in overall cesarean birth rates has not been demonstrated consistently [<a href="#rid15">15,43-49</a>].</p><p class="headingAnchor" id="H3181918818"><span class="h3">Choice of prostaglandin</span><span class="headingEndMark"> — </span>The optimal prostaglandin formulation, route of administration, dose, and frequency for cervical ripening has not been determined despite many studies. A network meta-analysis of 280 randomized trials reported the following relative findings, but reliable absolute rates of vaginal birth within 24 hours are difficult to cite because of variability in patients and procedures among the underlying trials [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> tablet ≥50 mcg was the treatment with the highest probability of achieving a vaginal birth within 24 hours. The prostaglandins with poorest probability of achieving a vaginal birth within 24 hours were the vaginal PGE2 pessary (normal release), oral misoprostol &lt;50 mcg, and intracervical PGE2.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vaginal <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> tablet ≥50 mcg was associated with a four-fold increase in the odds of uterine hyperstimulation compared with intracervical PGE2 (odds ratio [OR] 3.57, 95% CI 1.66-8.06). Vaginal misoprostol ≥50 mcg was also associated with a near three-fold increase in the odds of hyperstimulation compared with slow-release vaginal PGE2 (OR 2.73, 95% CI 1.08-7.40).</p><p></p><p>Most of the studies used four hourly and some opted for six hourly treatment regimens. Although 50 mcg <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> was more effective than 25 mcg for achieving birth within 24 hours, the 25 mcg dose is more commonly used because of its better safety profile.</p><p>Patient and provider preferences regarding factors such as convenience, side effects, and cost should also be considered. </p><p class="headingAnchor" id="H3899460526"><span class="h2">Use of specific agents</span></p><p class="headingAnchor" id="H1917456107"><span class="h3">Prostaglandin E1 (misoprostol)</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> (Cytotec) is a prostaglandin E1 analog available as 100 and 200 mcg tablets, which can be broken to provide 25 or 50 mcg doses. It is rapidly absorbed from both the oral and vaginal routes [<a href="#rid50">50</a>]. Either route is reasonable; one route of administration is not clearly better than another in terms of important health outcomes, although available data are difficult to interpret because of differences in dosing [<a href="#rid46">46</a>]. The 25 mcg dose is generally preferred because adverse effects are mostly seen at higher doses [<a href="#rid1">1</a>]. The existence of a toxic dose of misoprostol has not been determined and cumulative total daily doses of 1600 mcg have been tolerated, with only symptoms of gastrointestinal discomfort [<a href="#rid51">51</a>].</p><p>The approved indication for <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> is treatment and prevention of gastric ulcer disease related to chronic nonsteroidal anti-inflammatory drug use. Administration of this drug for cervical ripening and labor induction is considered an off-label use in the United States. However, there is good evidence that it is an effective alternative to PGE2 preparations for cervical ripening and labor induction [<a href="#rid15">15,47-49,52</a>]. The American College of Obstetricians and Gynecologists (ACOG) has stated that use of misoprostol appears as safe and efficacious as other prostaglandin agents when used as a cervical ripening and/or labor induction agent as described below [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H1917456160"><span class="h4">Vaginal administration</span><span class="headingEndMark"> — </span>The optimal dose and timing interval of intravaginally applied <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> have not been determined [<a href="#rid47">47,53-56</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> 25 mcg vaginally, with redosing intervals of three to six hours is a common dose [<a href="#rid1">1,47,57-61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, four hours after the final <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> dose. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In some situations, such as inadequate uterine activity at lower doses, <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> 50 mcg vaginally at six-hour intervals may be appropriate; however, this dose has been associated with a higher risk of tachysystole [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> vaginal insert consisting of a controlled-release, retrievable polymer chip for gradual delivery of 200 mcg over 24 hours is available in some countries but not in the United States. In a large randomized trial comparing patients who received the misoprostol vaginal insert with those receiving a <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> vaginal insert, use of the misoprostol vaginal insert resulted in a significantly shorter median time to vaginal birth (21.5 versus 32.8 hours) but also resulted in a higher chance of uterine tachysystole requiring intervention (13.3 versus 4 percent) and did not change the chance of cesarean birth [<a href="#rid62">62</a>].</p><p></p><p>A meta-analysis reported that the 50 mcg dose vaginally was more effective than the 25 mcg dose (eg, resulted in a higher chance of birth after a single dose and of delivery within 24 hours, and a lower chance of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> use), but the 25 mcg dose resulted in lower rates of tachysystole, cesarean birth for nonreassuring FHR, neonatal intensive care units admission, and meconium passage [<a href="#rid63">63</a>].</p><p class="headingAnchor" id="H1917456172"><span class="h4">Oral administration</span><span class="headingEndMark"> — </span>When administered orally, the concentration peaks sooner and declines more rapidly than with vaginal administration  (<a class="graphic graphic_figure graphicRef71621" href="/d/graphic/71621.html" rel="external">figure 2</a>) [<a href="#rid50">50</a>]. The dose recommended by the World Health Organization is 25 mcg orally, with two-hour redosing intervals [<a href="#rid60">60</a>]. </p><p><a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, four hours after the final <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> dose.</p><p>Randomized trials have used a wide variety of oral doses (20 to 200 mcg) and intervals of administration (1 to 6 hours) [<a href="#rid64">64</a>]. Despite many trials, there is no clear consensus as to the optimum oral dose or dosing interval, and whether the patient should swallow a tablet versus a titrated oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> solution.</p><p>A 2021 meta-analysis supported the use of low-dose oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> for induction of labor and suggested that a starting dose of 25 mcg may offer a good balance of efficacy and safety [<a href="#rid49">49</a>]. It should be noted, however, that the authors considered the recommendation to have only moderate-to-low certainty given imprecision, inconsistency, and study limitations. Included trials compared oral misoprostol protocols of one‐ to two‐hourly versus four‐ to six‐hourly dosing; doses of 20 to 25 mcg versus 50 mcg; and 20 mcg hourly titrated versus 25 mcg two‐hourly static. </p><p>A subsequent trial investigated a higher dose of oral <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>. This trial compared oral misoprostol 100 mcg every four hours for up to two doses with vaginal misoprostol 25 mcg every three hours for up to five doses, followed by a standardized <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> protocol, in 1322 patients at term [<a href="#rid61">61</a>]. Both groups had a similar rate of vaginal birth at first induction attempt (78 percent) and time to delivery (19.7 hours). The participants who were randomized to vaginal dosing had less tachysystole with fetal heart rate changes (3.5 versus 5.9 percent, RR 0.59, 95% CI 0.40-0.87). There were no statistically significant differences between groups in neonatal five-minute Apgar score, umbilical cord blood pH less than 7.0, or sepsis, but the participants who were randomized to vaginal dosing had a higher frequency of neonatal intensive care unit admission (2.0 versus 1.0 percent, adjusted RR 2.08, 95% CI 1.06-4.09), which was attributed to increased frequency of neonatal assisted ventilation or urgent pediatric surgical intervention. Some limitations of the trial are that maternal side effects (fever, nausea, vomiting, diarrhea) were not evaluated; it was underpowered to detect modest differences in neonatal outcomes; and potential lack of generalizability (mean age of participants: 26 to 27 years, nulliparas: approximately 50 percent, internal fetal monitoring: approximately 75 percent, white race: approximately 5 percent, oligohydramnios as indication for induction: 35 to 37 percent, mean body mass index [BMI] at first prenatal visit: approximately 30.7 kg/m<sup>2</sup>). </p><p class="headingAnchor" id="H1917456184"><span class="h4">Buccal or sublingual administration</span><span class="headingEndMark"> — </span>Other approaches to use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, including buccal and sublingual administration, have been described, but are less well studied and should be considered investigational [<a href="#rid65">65-68</a>]. These routes of administration may avoid first-pass hepatic metabolism associated with oral ingestion and thus increase bioavailability similar to that achieved with vaginal administration. Pharmacokinetic data support the hypothesis that buccal and sublingual routes of administration are associated with more rapid onset of action and greater bioavailability than other routes [<a href="#rid65">65</a>]. Additionally, it is hypothesized that administration using these routes may reduce the risk of tachysystole by avoiding direct uterine effects.</p><p>However, a meta-analysis of five small trials (n = 740 patients) of sublingual versus vaginal administration found no statistically significant differences in rate of vaginal birth not achieved within 24 hours (OR 1.27, 95% CI 0.87-1.84), uterine hyperstimulation syndrome (OR 1.20, 95% CI 0.61-2.33), or cesarean birth (OR 1.33, 95% CI 0.96-1.85), but uterine tachysystole was increased in the sublingual <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> group (OR 1.70, 95% CI 1.02-2.83) [<a href="#rid69">69</a>]. A subsequent well-designed trial (IMPROVE) including 300 patients suggested vaginal misoprostol may be superior to the buccal route: time to vaginal birth was reduced by eight hours, and fewer emergency cesareans were performed for FHR abnormalities [<a href="#rid70">70</a>]. Regardless of route, the first dose was 25 mcg and subsequent doses, if needed, were 50 mcg at intervals no sooner than four hours after the previous dose.</p><p class="headingAnchor" id="H92003902"><span class="h3">Prostaglandin E2</span><span class="headingEndMark"> — </span>Prepidil and Cervidil are two PGE2 preparations commercially available for cervical ripening in the United States. Other formulations are available worldwide (eg, Prostin E2 gel containing 1 mg or 2 mg <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> for vaginal insertion, Prostin E2 0.5 mg tablet for oral administration). These drugs are more costly than <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>.</p><p class="headingAnchor" id="H2274829"><span class="h4">Prepidil</span><span class="headingEndMark"> — </span>Prepidil<strong> </strong>contains 0.5 mg of <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> in 2.5 mL of gel for endocervical administration. The dose can be repeated in 6 to 12 hours if cervical change is inadequate and uterine activity is minimal following the first dose. The manufacturer recommends that the maximum cumulative dose of dinoprostone not exceed 1.5 mg (ie, three doses) within a 24-hour period.</p><p>The time interval between the final dose and initiation of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a>, if necessary, should be 6 to 12 hours because of the potential for uterine tachysystole with concurrent oxytocin and PGE2 prostaglandin administration. (See  <a class="medical medical_review" href="/d/html/4476.html" rel="external">"Induction of labor with oxytocin", section on 'Complications of induction'</a>.)</p><p class="headingAnchor" id="H2274844"><span class="h4">Cervidil</span><span class="headingEndMark"> — </span>Cervidil is a vaginal insert containing 10 mg of <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> in a timed-release formulation (the medication is released at 0.3 mg/hour). The insert is left in place until active labor begins or for 12 hours. </p><p><a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, anytime beyond 30 minutes after removal of the insert.</p><p>A theoretical advantage of the vaginal insert over the gel formulation is that the vaginal insert can be removed in cases of uterine tachysystole or abnormalities of the FHR tracing [<a href="#rid71">71,72</a>], although this possibility has not translated into better clinical outcomes than other ripening methods.</p><p class="headingAnchor" id="H2277400"><span class="h1">COMBINATION THERAPY (BALLOON CATHETER PLUS A PROSTAGLANDIN OR OXYTOCIN)</span><span class="headingEndMark"> — </span>Some, but not all, trials have shown that the concurrent use of mechanical and pharmacologic ripening methods may have modest benefits over the use of a single method alone, without increasing the risk of adverse obstetric or perinatal outcomes. In a network meta-analysis (30 randomized trials, 6465 pregnancies), the combination of a balloon catheter plus a prostaglandin (cBC/P) or a balloon catheter plus <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> (cBC/O) compared with a balloon catheter alone [<a href="#rid73">73</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Hastened the time to vaginal birth (cBC/P: -2.9 hours, 95% CI -5.7 to 0; cBC/O: -4.2 hours, 95% CI -6.5 to -1.9).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased the chance of birth within 24 hours (cBC/P: odds ratio [OR] 1.80, 95% CI 1.02-3.20; cBC/O: OR 2.04, 95% CI 1.29-3.24).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Did not significantly affect the risk for cesarean birth (cBC/P: OR 0.89, 95% CI 0.65-1.20; cBC/O: OR 0.99, 95% CI 0.74-1.33) or adverse events (chorioamnionitis, endometritis, tachysystole, meconium, neonatal intensive care unit admission, postpartum hemorrhage).</p><p></p><p>A meta-analysis that evaluated the efficacy of mechanical methods plus a prostaglandin or <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> versus medication alone found combined therapy had no clear benefit for achieving vaginal birth within 24 hours [<a href="#rid19">19</a>]. </p><p>Data are insufficient to determine whether to routinely use combination therapy, which combination to use (cBC/P or cBC/O), and the optimum protocol.</p><p class="headingAnchor" id="H15"><span class="h1">OTHER APPROACHES</span></p><p class="headingAnchor" id="H2077616035"><span class="h2">Other cervical ripening drugs and techniques</span><span class="headingEndMark"> — </span>Relaxin [<a href="#rid74">74-76</a>], nitric oxide donors (eg, <a class="drug drug_general" data-topicid="8581" href="/d/drug information/8581.html" rel="external">isosorbide mononitrate</a>) [<a href="#rid77">77,78</a>], <a class="drug drug_general" data-topicid="8657" href="/d/drug information/8657.html" rel="external">hyaluronidase</a> [<a href="#rid79">79</a>], corticosteroids [<a href="#rid80">80</a>], <a class="drug drug_general" data-topicid="8846" href="/d/drug information/8846.html" rel="external">castor oil</a> [<a href="#rid81">81</a>], sexual intercourse [<a href="#rid82">82,83</a>], breast stimulation [<a href="#rid84">84</a>], and herbal preparations [<a href="#rid85">85</a>] have been used for cervical ripening, although we recommend not using these approaches because of limited data regarding safety and/or efficacy and the availability of proven alternatives.</p><p>Extraamniotic <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> infusion is a procedure in which sterile saline is infused continuously via a balloon catheter placed in the extraamniotic space [<a href="#rid86">86-89</a>]. However, it does not have a clear advantage over other methods (balloon catheter alone, prostaglandins) [<a href="#rid90">90-92</a>].</p><p class="headingAnchor" id="H2205437822"><span class="h1">SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Management of cervical ripening in the following two special populations is reviewed separately.</p><p class="headingAnchor" id="H3781665180"><span class="h2">Fetal demise</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/6740.html" rel="external">"Stillbirth: Maternal care", section on 'Birth'</a>.)</p><p class="headingAnchor" id="H4115764486"><span class="h2">Previous cesarean birth</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/d/html/4451.html" rel="external">"Cervical ripening and induction of labor after a prior cesarean birth"</a>.)</p><p class="headingAnchor" id="H2220708568"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113526.html" rel="external">"Society guideline links: Cervical ripening and labor induction"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Candidates </strong>– If the cervical status is unfavorable prior to induction, a ripening process is generally employed to shorten the duration of <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> administration and maximize the possibility of vaginal birth. If the cervix is favorable, oxytocin typically is initiated for induction without use of a cervical ripening agent. (See <a class="local">'Candidates'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There is no universally accepted definition of favorable or unfavorable cervix. Many clinicians consider a Bishop score &lt;6  (<a class="graphic graphic_table graphicRef65320" href="/d/graphic/65320.html" rel="external">table 1</a>) indicative of an unfavorable cervix and the need for a ripening agent, while others use a lower threshold (eg, ≤3 or 4). We recommend use of a cervical ripening agent for patients with a Bishop score ≤3 (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We consider both the Bishop score and noncervical factors when making this decision in patients with Bishop scores of 4, 5, or 6 and we feel cervical ripening is not required in patients with Bishop scores &gt;6. (See <a class="local">'Candidates'</a> above and  <a class="medical medical_review" href="/d/html/4476.html" rel="external">"Induction of labor with oxytocin", section on 'Assessing the chance of a successful induction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Protocol </strong>– Institutions should create and follow a clear protocol that delineates not only general cervical ripening issues, but also distinguishes differences between inpatient and outpatient ripening (eg, eligibility criteria). Once a cervical ripening agent is initiated, the process is typically continued until the cervix is favorable  (<a class="graphic graphic_algorithm graphicRef135242" href="/d/graphic/135242.html" rel="external">algorithm 1</a> and <a class="graphic graphic_table graphicRef65320" href="/d/graphic/65320.html" rel="external">table 1</a>). (See <a class="local">'Protocol'</a> above and <a class="local">'Inpatient versus outpatient cervical ripening'</a> above and <a class="local">'Initiation and discontinuation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of cervical ripening agent </strong>– For patients scheduled for labor induction with an unfavorable cervix, clinical outcomes are similar whether a balloon catheter or prostaglandins (E2 or E1) is used for cervical ripening. The choice of agent for a specific patient depends on multiple factors including institutional protocols, physician preferences, and patient preferences, which are influenced by convenience, cost, and side effects. (See <a class="local">'Choice of ripening agent for inpatient procedures'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Balloon catheter</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications </strong>– A low-lying placenta is a relative contraindication since the edge of the placenta may be disrupted by manipulation during placement of the device. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent2">Ruptured membranes are often considered a contraindication, but practice patterns in this setting vary. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> – The catheter is placed using aseptic technique. <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> can be started concurrently or after the catheter has been extruded or removed. (See <a class="local">'Device selection'</a> above and <a class="local">'Procedure'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Side effects</strong> – There are no systemic side effects, and a lower rate of tachysystole than prostaglandins. (See <a class="local">'Side effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostaglandins</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Contraindications</strong> – A prior cesarean birth or other prior major uterine surgery is a contraindication to use of <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a>, with practice variation regarding use of PGE2 in this setting. Preexisting regular painful uterine activity is a relative contraindication. (See <a class="local">'Contraindications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Administration</strong> –<strong> </strong>The most common drugs and doses are:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> 25 mcg vaginally, with redosing intervals of three to six hours is a common dose. <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, four hours after the final misoprostol dose. (See <a class="local">'Vaginal administration'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">Misoprostol</a> 25 mcg orally, with redosing at two-hour intervals. <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, four hours after the final misoprostol dose. (See <a class="local">'Oral administration'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Prepidil gel<strong> </strong>(0.5 mg of <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> in 2.5 mL of gel) for endocervical administration. The dose can be repeated in 6 to 12 hours for up to three doses in 24 hours if cervical change is inadequate and uterine activity is minimal following the first dose. <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, 6 to 12 hours after the final dose. (See <a class="local">'Prepidil'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Cervidil vaginal insert (10 mg of <a class="drug drug_general" data-topicid="9368" href="/d/drug information/9368.html" rel="external">dinoprostone</a> in a timed-release formulation). The insert is left in place until active labor begins or for 12 hours. <a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">Oxytocin</a> may be initiated, if necessary, 30 minutes after removal of the insert. (See <a class="local">'Cervidil'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Side effects</strong> – Side effects of prostaglandins include tachysystole, fever, chills, vomiting, and diarrhea. The frequency of these side effects depends upon the type of prostaglandin, dose, and route of administration. Uterine contractile abnormalities occur in up to 30 percent of patients, depending upon the vehicle and route of administration; other systemic effects occur in up to 5 percent of cases. (See <a class="local">'Side effects'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Treatment of maternal discomfort is supportive (eg, <a class="drug drug_general" data-topicid="9242" href="/d/drug information/9242.html" rel="external">acetaminophen</a>, blanket, antiemetic).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If tachysystole with fetal heart rate (FHR) changes occurs after placement of a prostaglandin vaginal insert, removal of the insert usually reduces uterine contractility and normalizes FHR abnormalities. It may be possible to remove the remaining portion of a <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> pill, but prostaglandin gel cannot be removed. A tocolytic drug (eg, <a class="drug drug_general" data-topicid="9977" href="/d/drug information/9977.html" rel="external">terbutaline</a> 250 mcg subcutaneously) can be administered if in utero resuscitation is indicated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combined use of a balloon catheter and a prostaglandin or </strong><a class="drug drug_general" data-topicid="9734" href="/d/drug information/9734.html" rel="external">oxytocin</a> – The concurrent use of mechanical and pharmacologic ripening methods rather than a single method alone may have modest benefits (small reduction to time to vaginal birth, small increase in vaginal birth within 24 hours, but no change in cesarean rate), without increasing the risk of adverse obstetric or perinatal outcomes. If a provider chooses to give oxytocin concurrently, either a fixed low dose or standard incremental dose regimen is acceptable  (<a class="graphic graphic_table graphicRef69023" href="/d/graphic/69023.html" rel="external">table 2</a>). (See <a class="local">'Combination therapy (balloon catheter plus a prostaglandin or oxytocin)'</a> above.)</p><p></p><p class="headingAnchor" id="H191579129"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Deborah A Wing, MD, MBA, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">ACOG Committee on Practice Bulletins -- Obstetrics. ACOG Practice Bulletin No. 107: Induction of labor. Obstet Gynecol 2009; 114:386. Reaffirmed 2020.</a></li><li><a class="nounderline abstract_t">Alfirevic Z, Gyte GM, Nogueira Pileggi V, et al. Home versus inpatient induction of labour for improving birth outcomes. Cochrane Database Syst Rev 2020; 8:CD007372.</a></li><li><a class="nounderline abstract_t">Dong S, Khan M, Hashimi F, et al. Inpatient versus outpatient induction of labour: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2020; 20:382.</a></li><li><a class="nounderline abstract_t">McDonagh M, Skelly AC, Tilden E, et al. Outpatient Cervical Ripening: A Systematic Review and Meta-analysis. Obstet Gynecol 2021; 137:1091.</a></li><li><a class="nounderline abstract_t">Pierce-Williams R, Lesser H, Saccone G, et al. Outpatient cervical ripening with balloon catheters. Obstet Gynecol 2022.</a></li><li><a class="nounderline abstract_t">Vogel JP, Osoti AO, Kelly AJ, et al. Pharmacological and mechanical interventions for labour induction in outpatient settings. Cochrane Database Syst Rev 2017; 9:CD007701.</a></li><li><a class="nounderline abstract_t">Khan H, Buaki-Sogo MA, Barlow P, et al. Efficacy of pharmacological and mechanical cervical priming methods for induction of labour and their applicability for outpatient management: A systematic review of randomised controlled trials. Eur J Obstet Gynecol Reprod Biol 2023; 287:80.</a></li><li><a class="nounderline abstract_t">Sharp AN, Stock SJ, Alfirevic Z. Outpatient induction of labour in the UK: a survey of practice. Eur J Obstet Gynecol Reprod Biol 2016; 204:21.</a></li><li><a class="nounderline abstract_t">Sciscione AC, Muench M, Pollock M, et al. Transcervical Foley catheter for preinduction cervical ripening in an outpatient versus inpatient setting. Obstet Gynecol 2001; 98:751.</a></li><li><a class="nounderline abstract_t">Sciscione AC, Bedder CL, Hoffman MK, et al. The timing of adverse events with Foley catheter preinduction cervical ripening; implications for outpatient use. Am J Perinatol 2014; 31:781.</a></li><li><a class="nounderline abstract_t">Kuper SG, Jauk VC, George DM, et al. Outpatient Foley Catheter for Induction of Labor in Parous Women: A Randomized Controlled Trial. Obstet Gynecol 2018; 132:94.</a></li><li><a class="nounderline abstract_t">Ausbeck EB, Jauk VC, Xue Y, et al. Outpatient Foley Catheter for Induction of Labor in Nulliparous Women: A Randomized Controlled Trial. Obstet Gynecol 2020; 136:597.</a></li><li><a class="nounderline abstract_t">Austin K, Chambers GM, de Abreu Lourenco R, et al. Cost-effectiveness of term induction of labour using inpatient prostaglandin gel versus outpatient Foley catheter. Aust N Z J Obstet Gynaecol 2015; 55:440.</a></li><li><a class="nounderline abstract_t">Vaknin Z, Kurzweil Y, Sherman D. Foley catheter balloon vs locally applied prostaglandins for cervical ripening and labor induction: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:418.</a></li><li><a class="nounderline abstract_t">Fox NS, Saltzman DH, Roman AS, et al. Intravaginal misoprostol versus Foley catheter for labour induction: a meta-analysis. BJOG 2011; 118:647.</a></li><li><a class="nounderline abstract_t">Chen W, Xue J, Peprah MK, et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. BJOG 2016; 123:346.</a></li><li><a class="nounderline abstract_t">El Maradny E, Kanayama N, Halim A, et al. Biochemical changes in the cervical mucus after application of laminaria tent. Acta Obstet Gynecol Scand 1996; 75:203.</a></li><li><a class="nounderline abstract_t">Bromwich KA, McCoy JA, Cahill AG, et al. Association between intracervical Foley balloon and clinical chorioamnionitis among patients with group B streptococcus colonization undergoing induction with standardized labor management. Am J Obstet Gynecol MFM 2023; 5:101167.</a></li><li><a class="nounderline abstract_t">de Vaan MD, Ten Eikelder ML, Jozwiak M, et al. Mechanical methods for induction of labour. Cochrane Database Syst Rev 2023; 3:CD001233.</a></li><li><a class="nounderline abstract_t">McMaster K, Sanchez-Ramos L, Kaunitz AM. Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis. Obstet Gynecol 2015; 126:539.</a></li><li><a class="nounderline abstract_t">Battarbee AN, Palatnik A, Peress DA, Grobman WA. Association of Early Amniotomy After Foley Balloon Catheter Ripening and Duration of Nulliparous Labor Induction. Obstet Gynecol 2016; 128:592.</a></li><li><a class="nounderline abstract_t">Levy R, Ferber A, Ben-Arie A, et al. A randomised comparison of early versus late amniotomy following cervical ripening with a Foley catheter. BJOG 2002; 109:168.</a></li><li><a class="nounderline abstract_t">Gomez Slagle HB, Fonge YN, Caplan R, et al. Early vs expectant artificial rupture of membranes following Foley catheter ripening: a randomized controlled trial. Am J Obstet Gynecol 2022; 226:724.e1.</a></li><li><a class="nounderline abstract_t">Levy R, Kanengiser B, Furman B, et al. A randomized trial comparing a 30-mL and an 80-mL Foley catheter balloon for preinduction cervical ripening. Am J Obstet Gynecol 2004; 191:1632.</a></li><li><a class="nounderline abstract_t">Delaney S, Shaffer BL, Cheng YW, et al. Labor induction with a Foley balloon inflated to 30 mL compared with 60 mL: a randomized controlled trial. Obstet Gynecol 2010; 115:1239.</a></li><li><a class="nounderline abstract_t">Schoen CN, Saccone G, Backley S, et al. Increased single-balloon Foley catheter volume for induction of labor and time to delivery: a systematic review and meta-analysis. Acta Obstet Gynecol Scand 2018; 97:1051.</a></li><li><a class="nounderline abstract_t">Fruhman G, Gavard JA, Amon E, et al. Tension compared to no tension on a Foley transcervical catheter for cervical ripening: a randomized controlled trial. Am J Obstet Gynecol 2017; 216:67.e1.</a></li><li><a class="nounderline abstract_t">Gibson KS, Mercer BM, Louis JM. Inner thigh taping vs traction for cervical ripening with a Foley catheter: a randomized controlled trial. Am J Obstet Gynecol 2013; 209:272.e1.</a></li><li><a class="nounderline abstract_t">Cromi A, Ghezzi F, Agosti M, et al. Is transcervical Foley catheter actually slower than prostaglandins in ripening the cervix? A randomized study. Am J Obstet Gynecol 2011; 204:338.e1.</a></li><li><a class="nounderline abstract_t">Lassey SC, Haber HR, Kanbergs A, et al. Six versus twelve hours of single-balloon catheter placement with oxytocin administration for labor induction: a randomized controlled trial. Am J Obstet Gynecol 2021; 224:611.e1.</a></li><li><a class="nounderline abstract_t">Bleicher I, Dikopoltsev E, Kadour-Ferro E, et al. Double-Balloon Device for 6 Compared With 12 Hours for Cervical Ripening: A Randomized Controlled Trial. Obstet Gynecol 2020; 135:1153.</a></li><li><a class="nounderline abstract_t">Kamarudzman N, Omar SZ, Gan F, et al. Six vs 12 hours of Foley catheter balloon placement in the labor induction of multiparas with unfavorable cervixes: a randomized controlled trial. Am J Obstet Gynecol MFM 2023; 5:101142.</a></li><li><a class="nounderline abstract_t">Appadurai U, Gan F, Hong J, et al. Six compared with 12 hours of Foley balloon placement for labor induction in nulliparous women with unripe cervices: a randomized controlled trial. Am J Obstet Gynecol MFM 2023; 5:101157.</a></li><li><a class="nounderline abstract_t">Gelber S, Sciscione A. Mechanical methods of cervical ripening and labor induction. Clin Obstet Gynecol 2006; 49:642.</a></li><li><a class="nounderline abstract_t">Jozwiak M, Bloemenkamp KW, Kelly AJ, et al. Mechanical methods for induction of labour. Cochrane Database Syst Rev 2012; :CD001233.</a></li><li><a class="nounderline abstract_t">Gilson GJ, Russell DJ, Izquierdo LA, et al. A prospective randomized evaluation of a hygroscopic cervical dilator, Dilapan, in the preinduction ripening of patients undergoing induction of labor. Am J Obstet Gynecol 1996; 175:145.</a></li><li><a class="nounderline abstract_t">Saad AF, Villarreal J, Eid J, et al. A randomized controlled trial of Dilapan-S vs Foley balloon for preinduction cervical ripening (DILAFOL trial). Am J Obstet Gynecol 2019; 220:275.e1.</a></li><li><a class="nounderline abstract_t">Yount SM, Lassiter N. The pharmacology of prostaglandins for induction of labor. J Midwifery Womens Health 2013; 58:133.</a></li><li><a class="nounderline abstract_t">Pierce S, Bakker R, Myers DA, Edwards RK. Clinical Insights for Cervical Ripening and Labor Induction Using Prostaglandins. AJP Rep 2018; 8:e307.</a></li><li><a class="nounderline abstract_t">Makarem MH, Zahran KM, Abdellah MS, Karen MA. Early amniotomy after vaginal misoprostol for induction of labor: a randomized clinical trial. Arch Gynecol Obstet 2013; 288:261.</a></li><li><a class="nounderline abstract_t">Bostancı E, Eser A, Yayla Abide C, et al. Early amniotomy after dinoprostone insert used for the induction of labor: a randomized clinical trial. J Matern Fetal Neonatal Med 2018; 31:352.</a></li><li><a class="nounderline abstract_t">Rugarn O, Tipping D, Powers B, Wing DA. Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event. BJOG 2017; 124:796.</a></li><li><a class="nounderline abstract_t">Thomas J, Fairclough A, Kavanagh J, Kelly AJ. Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term. Cochrane Database Syst Rev 2014; :CD003101.</a></li><li><a class="nounderline abstract_t">Keirse MJ. Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience. J Reprod Med 1993; 38:89.</a></li><li><a class="nounderline abstract_t">Boulvain M, Kelly A, Irion O. Intracervical prostaglandins for induction of labour. Cochrane Database Syst Rev 2008; :CD006971.</a></li><li><a class="nounderline abstract_t">Alfirevic Z, Keeney E, Dowswell T, et al. Labour induction with prostaglandins: a systematic review and network meta-analysis. BMJ 2015; 350:h217.</a></li><li><a class="nounderline abstract_t">Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010; :CD000941.</a></li><li><a class="nounderline abstract_t">Austin SC, Sanchez-Ramos L, Adair CD. Labor induction with intravaginal misoprostol compared with the dinoprostone vaginal insert: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 202:624.e1.</a></li><li><a class="nounderline abstract_t">Kerr RS, Kumar N, Williams MJ, et al. Low-dose oral misoprostol for induction of labour. Cochrane Database Syst Rev 2021; 6:CD014484.</a></li><li><a class="nounderline abstract_t">Khan RU, El-Refaey H, Sharma S, et al. Oral, rectal, and vaginal pharmacokinetics of misoprostol. Obstet Gynecol 2004; 103:866.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019268s051lbl.pdf (Accessed on March 16, 2022).</li><li><a class="nounderline abstract_t">Muzonzini G, Hofmeyr GJ. Buccal or sublingual misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2004; :CD004221.</a></li><li><a class="nounderline abstract_t">Wing DA, Ortiz-Omphroy G, Paul RH. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997; 177:612.</a></li><li><a class="nounderline abstract_t">Farah LA, Sanchez-Ramos L, Rosa C, et al. Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction. Am J Obstet Gynecol 1997; 177:364.</a></li><li><a class="nounderline abstract_t">Wing DA. Labor induction with misoprostol. Am J Obstet Gynecol 1999; 181:339.</a></li><li><a class="nounderline abstract_t">Sanchez-Ramos L, Kaunitz AM, Wears RL, et al. Misoprostol for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol 1997; 89:633.</a></li><li><a class="nounderline abstract_t">Calder AA, Loughney AD, Weir CJ, Barber JW. Induction of labour in nulliparous and multiparous women: a UK, multicentre, open-label study of intravaginal misoprostol in comparison with dinoprostone. BJOG 2008; 115:1279.</a></li><li><a class="nounderline abstract_t">Tan TC, Yan SY, Chua TM, et al. A randomised controlled trial of low-dose misoprostol and dinoprostone vaginal pessaries for cervical priming. BJOG 2010; 117:1270.</a></li><li><a class="nounderline abstract_t">Tang J, Kapp N, Dragoman M, de Souza JP. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121:186.</a></li><li class="breakAll">WHO recommendations for induction of labour https://www.who.int/reproductivehealth/publications/maternal_perinatal_health/9789241501156/en/ (Accessed on March 16, 2022).</li><li><a class="nounderline abstract_t">Adhikari EH, McGuire J, Lo J, et al. Vaginal Compared With Oral Misoprostol Induction at Term: A Cluster Randomized Controlled Trial. Obstet Gynecol 2024; 143:256.</a></li><li><a class="nounderline abstract_t">Wing DA, Brown R, Plante LA, et al. Misoprostol vaginal insert and time to vaginal delivery: a randomized controlled trial. Obstet Gynecol 2013; 122:201.</a></li><li><a class="nounderline abstract_t">McMaster K, Sanchez-Ramos L, Kaunitz AM. Balancing the efficacy and safety of misoprostol: a meta-analysis comparing 25 versus 50 micrograms of intravaginal misoprostol for the induction of labour. BJOG 2015; 122:468.</a></li><li><a class="nounderline abstract_t">Weeks AD, Navaratnam K, Alfirevic Z. Simplifying oral misoprostol protocols for the induction of labour. BJOG 2017; 124:1642.</a></li><li><a class="nounderline abstract_t">Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod 2002; 17:332.</a></li><li><a class="nounderline abstract_t">Wolf SB, Sanchez-Ramos L, Kaunitz AM. Sublingual misoprostol for labor induction: a randomized clinical trial. Obstet Gynecol 2005; 105:365.</a></li><li><a class="nounderline abstract_t">Shetty A, Mackie L, Danielian P, et al. Sublingual compared with oral misoprostol in term labour induction: a randomised controlled trial. BJOG 2002; 109:645.</a></li><li><a class="nounderline abstract_t">Shetty A, Danielian P, Templeton A. Sublingual misoprostol for the induction of labor at term. Am J Obstet Gynecol 2002; 186:72.</a></li><li><a class="nounderline abstract_t">Souza AS, Amorim MM, Feitosa FE. Comparison of sublingual versus vaginal misoprostol for the induction of labour: a systematic review. BJOG 2008; 115:1340.</a></li><li><a class="nounderline abstract_t">Haas DM, Daggy J, Flannery KM, et al. A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial. Am J Obstet Gynecol 2019; 221:259.e1.</a></li><li><a class="nounderline abstract_t">Smith CV, Rayburn WF, Miller AM. Intravaginal prostaglandin E2 for cervical ripening and initiation of labor. Comparison of a multidose gel and single, controlled-release pessary. J Reprod Med 1994; 39:381.</a></li><li><a class="nounderline abstract_t">Witter FR, Rocco LE, Johnson TR. A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term. Am J Obstet Gynecol 1992; 166:830.</a></li><li><a class="nounderline abstract_t">Orr L, Reisinger-Kindle K, Roy A, et al. Combination of Foley and prostaglandins versus Foley and oxytocin for cervical ripening: a network meta-analysis. Am J Obstet Gynecol 2020; 223:743.e1.</a></li><li><a class="nounderline abstract_t">Weiss G, Teichman S, Stewart D, et al. A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies. Ann N Y Acad Sci 2009; 1160:385.</a></li><li><a class="nounderline abstract_t">Bell RJ, Permezel M, MacLennan A, et al. A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening. Obstet Gynecol 1993; 82:328.</a></li><li><a class="nounderline abstract_t">Brennand JE, Calder AA, Leitch CR, et al. Recombinant human relaxin as a cervical ripening agent. Br J Obstet Gynaecol 1997; 104:775.</a></li><li><a class="nounderline abstract_t">Ghosh A, Lattey KR, Kelly AJ. Nitric oxide donors for cervical ripening and induction of labour. Cochrane Database Syst Rev 2016; 12:CD006901.</a></li><li><a class="nounderline abstract_t">Abu-Zaid A, Alshahrani MS, Al-Matary A, et al. Isosorbide mononitrate for cervical ripening during labour induction: A systematic review and meta-analysis of 23 randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2022; 276:38.</a></li><li><a class="nounderline abstract_t">Kavanagh J, Kelly AJ, Thomas J. Hyaluronidase for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003097.</a></li><li><a class="nounderline abstract_t">Kavanagh J, Kelly AJ, Thomas J. Corticosteroids for cervical ripening and induction of labour. Cochrane Database Syst Rev 2006; :CD003100.</a></li><li><a class="nounderline abstract_t">Kelly AJ, Kavanagh J, Thomas J. Castor oil, bath and/or enema for cervical priming and induction of labour. Cochrane Database Syst Rev 2013; :CD003099.</a></li><li><a class="nounderline abstract_t">Kavanagh J, Kelly AJ, Thomas J. Sexual intercourse for cervical ripening and induction of labour. Cochrane Database Syst Rev 2001; :CD003093.</a></li><li><a class="nounderline abstract_t">Omar NS, Tan PC, Sabir N, et al. Coitus to expedite the onset of labour: a randomised trial. BJOG 2013; 120:338.</a></li><li><a class="nounderline abstract_t">Kavanagh J, Kelly AJ, Thomas J. Breast stimulation for cervical ripening and induction of labour. Cochrane Database Syst Rev 2005; :CD003392.</a></li><li><a class="nounderline abstract_t">McFarlin BL, Gibson MH, O'Rear J, Harman P. A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice. J Nurse Midwifery 1999; 44:205.</a></li><li><a class="nounderline abstract_t">Lyndrup J, Nickelsen C, Weber T, et al. Induction of labour by balloon catheter with extra-amniotic saline infusion (BCEAS): a randomised comparison with PGE2 vaginal pessaries. Eur J Obstet Gynecol Reprod Biol 1994; 53:189.</a></li><li><a class="nounderline abstract_t">Vengalil SR, Guinn DA, Olabi NF, et al. A randomized trial of misoprostol and extra-amniotic saline infusion for cervical ripening and labor induction. Obstet Gynecol 1998; 91:774.</a></li><li><a class="nounderline abstract_t">Yuen PM, Pang HY, Chung T, Chang A. Cervical ripening before induction of labour in patients with an unfavourable cervix: a comparative randomized study of the Atad Ripener Device, prostaglandin E2 vaginal pessary, and prostaglandin E2 intracervical gel. Aust N Z J Obstet Gynaecol 1996; 36:291.</a></li><li><a class="nounderline abstract_t">Atad J, Hallak M, Ben-David Y, et al. Ripening and dilatation of the unfavourable cervix for induction of labour by a double balloon device: experience with 250 cases. Br J Obstet Gynaecol 1997; 104:29.</a></li><li><a class="nounderline abstract_t">Guinn DA, Davies JK, Jones RO, et al. Labor induction in women with an unfavorable Bishop score: randomized controlled trial of intrauterine Foley catheter with concurrent oxytocin infusion versus Foley catheter with extra-amniotic saline infusion with concurrent oxytocin infusion. Am J Obstet Gynecol 2004; 191:225.</a></li><li><a class="nounderline abstract_t">Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. Obstet Gynecol 2006; 107:234.</a></li><li><a class="nounderline abstract_t">Lin MG, Reid KJ, Treaster MR, et al. Transcervical Foley catheter with and without extraamniotic saline infusion for labor induction: a randomized controlled trial. Obstet Gynecol 2007; 110:558.</a></li></ol></div><div id="topicVersionRevision">Topic 5398 Version 123.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19623003" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACOG Practice Bulletin No. 107: Induction of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32852803" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Home versus inpatient induction of labour for improving birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32605542" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Inpatient versus outpatient induction of labour: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33752219" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Outpatient Cervical Ripening: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Outpatient cervical ripening with balloon catheters</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28901007" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Pharmacological and mechanical interventions for labour induction in outpatient settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37300982" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Efficacy of pharmacological and mechanical cervical priming methods for induction of labour and their applicability for outpatient management: A systematic review of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27513897" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Outpatient induction of labour in the UK: a survey of practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704164" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Transcervical Foley catheter for preinduction cervical ripening in an outpatient versus inpatient setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347259" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The timing of adverse events with Foley catheter preinduction cervical ripening; implications for outpatient use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889751" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Outpatient Foley Catheter for Induction of Labor in Parous Women: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32769658" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Outpatient Foley Catheter for Induction of Labor in Nulliparous Women: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26173911" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cost-effectiveness of term induction of labour using inpatient prostaglandin gel versus outpatient Foley catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20605133" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Foley catheter balloon vs locally applied prostaglandins for cervical ripening and labor induction: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21332637" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Intravaginal misoprostol versus Foley catheter for labour induction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26538408" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8607329" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Biochemical changes in the cervical mucus after application of laminaria tent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37741625" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association between intracervical Foley balloon and clinical chorioamnionitis among patients with group B streptococcus colonization undergoing induction with standardized labor management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36996264" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Mechanical methods for induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26244535" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Evaluation of a Transcervical Foley Catheter as a Source of Infection: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27500341" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Association of Early Amniotomy After Foley Balloon Catheter Ripening and Duration of Nulliparous Labor Induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11888099" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A randomised comparison of early versus late amniotomy following cervical ripening with a Foley catheter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35135684" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Early vs expectant artificial rupture of membranes following Foley catheter ripening: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15547534" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : A randomized trial comparing a 30-mL and an 80-mL Foley catheter balloon for preinduction cervical ripening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20502296" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Labor induction with a Foley balloon inflated to 30 mL compared with 60 mL: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29607491" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Increased single-balloon Foley catheter volume for induction of labor and time to delivery: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27640940" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Tension compared to no tension on a Foley transcervical catheter for cervical ripening: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23685080" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Inner thigh taping vs traction for cervical ripening with a Foley catheter: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272849" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is transcervical Foley catheter actually slower than prostaglandins in ripening the cervix? A randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33771496" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Six versus twelve hours of single-balloon catheter placement with oxytocin administration for labor induction: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32282603" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Double-Balloon Device for 6 Compared With 12 Hours for Cervical Ripening: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37643690" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Six vs 12 hours of Foley catheter balloon placement in the labor induction of multiparas with unfavorable cervixes: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37722505" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Six compared with 12 hours of Foley balloon placement for labor induction in nulliparous women with unripe cervices: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16885669" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mechanical methods of cervical ripening and labor induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22419277" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mechanical methods for induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8694040" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A prospective randomized evaluation of a hygroscopic cervical dilator, Dilapan, in the preinduction ripening of patients undergoing induction of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30790569" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A randomized controlled trial of Dilapan-S vs Foley balloon for preinduction cervical ripening (DILAFOL trial).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23590485" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The pharmacology of prostaglandins for induction of labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30377555" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical Insights for Cervical Ripening and Labor Induction Using Prostaglandins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430026" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Early amniotomy after vaginal misoprostol for induction of labor: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28110590" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Early amniotomy after dinoprostone insert used for the induction of labor: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27307397" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Induction of labour with retrievable prostaglandin vaginal inserts: outcomes following retrieval due to an intrapartum adverse event.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24941907" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Vaginal prostaglandin (PGE2 and PGF2a) for induction of labour at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8429533" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Prostaglandins in preinduction cervical ripening. Meta-analysis of worldwide clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18254122" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Intracervical prostaglandins for induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25656228" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Labour induction with prostaglandins: a systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20927722" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Vaginal misoprostol for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20430362" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Labor induction with intravaginal misoprostol compared with the dinoprostone vaginal insert: a systematic review and metaanalysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34155622" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Low-dose oral misoprostol for induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121558" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Oral, rectal, and vaginal pharmacokinetics of misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121558" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Oral, rectal, and vaginal pharmacokinetics of misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15495088" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Buccal or sublingual misoprostol for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9322632" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290452" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Randomized trial of two doses of the prostaglandin E1 analog misoprostol for labor induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454679" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Labor induction with misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9083326" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Misoprostol for cervical ripening and labor induction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18715414" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Induction of labour in nulliparous and multiparous women: a UK, multicentre, open-label study of intravaginal misoprostol in comparison with dinoprostone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20722643" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A randomised controlled trial of low-dose misoprostol and dinoprostone vaginal pessaries for cervical priming.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433680" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : WHO recommendations for misoprostol use for obstetric and gynecologic indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37989142" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Vaginal Compared With Oral Misoprostol Induction at Term: A Cluster Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23857539" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Misoprostol vaginal insert and time to vaginal delivery: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24989790" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Balancing the efficacy and safety of misoprostol: a meta-analysis comparing 25 versus 50 micrograms of intravaginal misoprostol for the induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28342186" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Simplifying oral misoprostol protocols for the induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821273" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Pharmacokinetics of different routes of administration of misoprostol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15684166" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sublingual misoprostol for labor induction: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118642" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Sublingual compared with oral misoprostol in term labour induction: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810088" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Sublingual misoprostol for the induction of labor at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18823486" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Comparison of sublingual versus vaginal misoprostol for the induction of labour: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31075246" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A comparison of vaginal versus buccal misoprostol for cervical ripening in women for labor induction at term (the IMPROVE trial): a triple-masked randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8064705" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Intravaginal prostaglandin E2 for cervical ripening and initiation of labor. Comparison of a multidose gel and single, controlled-release pessary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1550148" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A randomized trial of prostaglandin E2 in a controlled-release vaginal pessary for cervical ripening at term.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32387325" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Combination of Foley and prostaglandins versus Foley and oxytocin for cervical ripening: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19416225" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : A randomized, double-blind, placebo-controlled trial of relaxin for cervical ripening in post-delivery date pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8355929" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A randomized, double-blind, placebo-controlled trial of the safety of vaginal recombinant human relaxin for cervical ripening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9236640" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Recombinant human relaxin as a cervical ripening agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918616" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Nitric oxide donors for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35803111" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Isosorbide mononitrate for cervical ripening during labour induction: A systematic review and meta-analysis of 23 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625569" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Hyaluronidase for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16625570" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Corticosteroids for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23881775" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Castor oil, bath and/or enema for cervical priming and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11406072" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Sexual intercourse for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23145957" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Coitus to expedite the onset of labour: a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034897" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Breast stimulation for cervical ripening and induction of labour.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10380441" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A national survey of herbal preparation use by nurse-midwives for labor stimulation. Review of the literature and recommendations for practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200466" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Induction of labour by balloon catheter with extra-amniotic saline infusion (BCEAS): a randomised comparison with PGE2 vaginal pessaries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9572229" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : A randomized trial of misoprostol and extra-amniotic saline infusion for cervical ripening and labor induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8883753" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Cervical ripening before induction of labour in patients with an unfavourable cervix: a comparative randomized study of the Atad Ripener Device, prostaglandin E2 vaginal pessary, and prostaglandin E2 intracervical gel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988692" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ripening and dilatation of the unfavourable cervix for induction of labour by a double balloon device: experience with 250 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295370" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Labor induction in women with an unfavorable Bishop score: randomized controlled trial of intrauterine Foley catheter with concurrent oxytocin infusion versus Foley catheter with extra-amniotic saline infusion with concurrent oxytocin infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449106" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Induction of labor using a foley balloon, with and without extra-amniotic saline infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17766600" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Transcervical Foley catheter with and without extraamniotic saline infusion for labor induction: a randomized controlled trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
